

ABSTRACTS - 28th EACTS

149

QUALITY OF LIFE IN 3875 PATIENTS AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: ONE-YEAR DATA FROM THE GERMAN AORTIC VALVE REGISTRY

R. Lange¹, A. Beckmann², T. Neumann³, M. Krane¹, R. Zahn⁴, J.T. Cremer⁵, C. Hamm⁶, F. Mohr⁷

¹Department of Cardiovascular Surgery, German Heart Center Munich, Munich, Germany; ²Department of Cardiovascular Surgery, German Society for Thoracic and Cardiovascular Surgery, Berlin, Germany; ³Clinic for Cardiology, Universitätsklinikum Essen, Essen, Germany; ⁴Department of Cardiology, Heart Centre, Ludwigshafen, Ludwigshafen, Germany; ⁵Department of Cardiovascular Surgery, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; ⁶Cardiology, Kerckhoff Klinik Bad Nauheim, Bad Nauheim, Germany; ⁷Department of Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany

Objectives: For elderly patients with considerable comorbidities, transcatheter aortic valve implantation (TAVI) is an alternative therapeutic option. Beside the analysis of morbidity and mortality, one major aim of the German Aortic Valve Registry is the evaluation of TAVI regarding its effect on health-related quality of life (HrQoL).

Methods: In 2011, 3875 patients undergoing TAVI were included in the German Aortic Valve Registry. Patients were treated using a transapical (TAVI-TA; $n = 1181$) or transvascular (TAVI-TV; $n = 2694$) access. HrQoL was measured using the EuroQoL Five-Dimension (EQ-5D-3L) questionnaire preoperatively and 12 months postoperatively. Evaluated dimensions were mobility, self-care, usual activity, pain/discomfort and anxiety/depression. In addition, a visual analogue scale (VAS; 0-100%) for self-rating general health status was used.

Results: Preoperative and 1-year follow-up (FU) for HrQoL was completed in 1782 (66.1%) patients for TAVI-TV and 715 patients (60.5%) for TAVI-TA, respectively. One-year mortality was 21.0% for TAVI-TV and 27.8% for TAVI-TA. Reoperative VAS score for general health status was $52.8 \pm 20.2\%$ for TAVI-TV and $55 \pm 20.2\%$ for TAVI-TA. VAS scores improved to $59.3 \pm 20.7\%$ and $58.3 \pm 20.4\%$, respectively, at 1-year FU. A similar substantial improvement for patient dependent HrQoL between baseline and 1-year FU was observed for mobility of 7.6% (TAVI-TV) and 3.5% (TAVI-TA) (baseline: 33.5%/39.6%, 1-year FU: 41.1%/43.1%) and usual activity of 14.1% (TAVI-TV) and 9.1% (TAVI-TA) (baseline: 36.5%/44.7%, 1-year FU: 50.6%/53.8%), whereas only moderate changes were found for self care, pain/discomfort and anxiety/depression.

Conclusion: Treatment of patients suffering from aortic valve disease by either TAVI-TV or TAVI-TA leads to a substantial improvement in HrQoL, especially in terms of mobility and usual activities.